210 related articles for article (PubMed ID: 21691803)
101. CYP2D6*2 Polymorphism as a Predictor of Failed Outpatient Tramadol Therapy in Postherpetic Neuralgia Patients.
Nasare NV; Banerjee BD; Suryakantrao Deshmukh P; Mediratta PK; Saxena AK; Ahmed RS; Bhattacharya SN
Am J Ther; 2016; 23(3):e697-707. PubMed ID: 23567787
[TBL] [Abstract][Full Text] [Related]
102. Analgesic effects and assays of controlled-release tramadol and o-desmethyltramadol in cancer patients with pain.
Leppert W; Mikolajczak P
Curr Pharm Biotechnol; 2011 Feb; 12(2):306-12. PubMed ID: 21050160
[TBL] [Abstract][Full Text] [Related]
103. Development of a column-switching LC-MS/MS method of tramadol and its metabolites in hair and application to a pharmacogenetic study.
Yu H; Choi M; Jang JH; Park B; Seo YH; Jeong CH; Bae JW; Lee S
Arch Pharm Res; 2018 May; 41(5):554-563. PubMed ID: 29524157
[TBL] [Abstract][Full Text] [Related]
104. Pharmacokinetics of intravenous tramadol in dogs.
McMillan CJ; Livingston A; Clark CR; Dowling PM; Taylor SM; Duke T; Terlinden R
Can J Vet Res; 2008 Jul; 72(4):325-31. PubMed ID: 18783021
[TBL] [Abstract][Full Text] [Related]
105. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
106. CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids.
Knisely MR; Carpenter JS; Draucker CB; Skaar T; Broome ME; Holmes AM; Von Ah D
Appl Nurs Res; 2017 Dec; 38():107-110. PubMed ID: 29241501
[TBL] [Abstract][Full Text] [Related]
107. CYP2D6 Basic Genotyping of Patients with Chronic Pain Receiving Tramadol or Codeine. A Study in a Greek Cohort.
Batistaki C; Chrona E; Kostroglou A; Kostopanagiotou G; Gazouli M
Pain Med; 2020 Nov; 21(11):3199-3204. PubMed ID: 32443139
[TBL] [Abstract][Full Text] [Related]
108. Factors related to seizure in tramadol poisoning and its blood concentration.
Taghaddosinejad F; Mehrpour O; Afshari R; Seghatoleslami A; Abdollahi M; Dart RC
J Med Toxicol; 2011 Sep; 7(3):183-8. PubMed ID: 21735309
[TBL] [Abstract][Full Text] [Related]
109. A genome-wide association study of tramadol metabolism from post-mortem samples.
Wendt FR; Rahikainen AL; King JL; Sajantila A; Budowle B
Pharmacogenomics J; 2020 Feb; 20(1):94-103. PubMed ID: 30971809
[TBL] [Abstract][Full Text] [Related]
110. CYP2D6 Expression in Veterans Experiencing Opioid Overdose: A Postmortem Review.
Boyle J; Stock CJ
Pharmgenomics Pers Med; 2020; 13():289-293. PubMed ID: 32848444
[TBL] [Abstract][Full Text] [Related]
111. A consideration of CYP2D6 genetic variations in the Ghanaian population as a potential 'culprit' for the tramadol 'abuse crisis'.
Thomford NE; Abraham SA; Nyarko SB; Biney RP
BMC Med Genomics; 2024 Jan; 17(1):28. PubMed ID: 38254077
[TBL] [Abstract][Full Text] [Related]
112. The effects of cytochrome P450 2D6 inhibitors on a high-dose tramadol taper for medically supervised opioid withdrawal: a retrospective chart review.
Stump T; Cather J; Moore PS
J Addict Dis; 2021; 39(1):81-87. PubMed ID: 32921297
[No Abstract] [Full Text] [Related]
113. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.
Thomas CD; Parvataneni HK; Gray CF; Deen JT; Prieto HA; Pulido LF; Elsey AR; Elwood EN; Starostik P; Gong Y; Fillingim RB; Johnson JA; Cavallari LH
Genet Med; 2021 Apr; 23(4):621-628. PubMed ID: 33420349
[TBL] [Abstract][Full Text] [Related]
114. Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats.
Bao SS; Tang PF; Gao NY; Xiao ZX; Qian JC; Zheng L; Hu GX; Xu HH
PeerJ; 2023; 11():e16051. PubMed ID: 37719112
[TBL] [Abstract][Full Text] [Related]
115. An Investigation of O-Demethyl Tramadol/Tramadol Ratio for Cytochrome P450 2D6 Phenotyping: The CYTRAM Study.
De La Gastine B; Percevault S; Varin L; Richard N; Fobe F; Plaud B; Daccache G; Compere V; Parienti JJ; Coquerel A; Loilier M; Bleyzac N; Bourguignon L; Goutelle S; Lelong-Boulouard V
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297612
[TBL] [Abstract][Full Text] [Related]
116. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; ():. PubMed ID: 32598307
[TBL] [Abstract][Full Text] [Related]
117. Tramadol intoxication in children: An emerging issue.
Drevin G; Picard N; Baudriller A; Pena-Martin M; Ferec S; Leuger L; Briet M; Abbara C
Therapie; 2024 Jun; ():. PubMed ID: 38871543
[TBL] [Abstract][Full Text] [Related]
118. Using tramadol to measure CYP2D6 metabolism in critically ill adults.
Lane K; Dixon JJ; McKeown D; Johnston A; van Schaik RH; van Fessem M; MacPhee IA; Philips BJ
Intensive Care Med; 2014 Aug; 40(8):1177-8. PubMed ID: 24968714
[No Abstract] [Full Text] [Related]
119. PharmGKB summary: tramadol pathway.
Gong L; Stamer UM; Tzvetkov MV; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Jul; 24(7):374-80. PubMed ID: 24849324
[No Abstract] [Full Text] [Related]
120. Transient depersonalisation/derealisation syndrome from tramadol.
Thumtecho S; Wainipitapong S; Tantakitti P
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37280010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
